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Objective: To evaluate the efficacy and safety of vancomycin constant-rate infusion over 24 h in the treatment of Gram- 
positive bone infections, 
Methods: Vancomycin (40 mg/kg/day) was administered without a loading dose to 15 patients (12 male, three female) 
aged 23-90 years, weighing 46-85 kg, with postoperative chronic bone and joint infections. The 24-h dose was adjusted 
to  maintain plasma levels between 25 and 35 mg/L. Mean duration of therapy was 6.2 months (4-8.5) via a portable 
infusion pump. Sites of infection included hip and femur (lo), tibia (three), patella (one) and vertebrae (one). 
Sequestrectomy (two), removal of material (7/8 prosthetic hips, 1/5 metal implants) and debridement (two) were 
performed at the beginning of the treatment. Involved bacteria included Staphylococcus aureus (eight, six methicillin 
resistant), S. epidermidis (four methicillin-resistant), Enterococcus faecalis (one), Enterococcus avium (one) and Strepto- 
coccus bovis (one). 
Results: MIC of vancomycin ranged from 1 t o  4 mg/L. The mean vancomycin bone concentration when available was 
67.7k38.9 vg/L. Based on a mean post-treatment follow-up of 14+4 months (6-20.6), cure was achieved in 10 patients 
(66.6%). Failures were related to the inability to remove the infected prosthesis (one) or implants (three) and to the 
persistence of a deep wound abcess (one). Adverse events included pruritus (four cases), tinnitus (two), mild transient 
elevation of creatinine level (three) and transient neutropenia (two). Vancomycin was maintained in all the patients. 
Conclusions: Prolonged treatment with vancomycin constant-rate infusion is effective and safe for treatment of Gram- 
positive chronic bone and joint infections, providing that complete surgical debridement and prosthetic material removal 
are performed. 
Key words: vancomycin, continuous intravenous infusion, chronic bone infection 
Treatment of chronic Gram-positive bone and joint 
infections, whether due to trauma or surgical pro- 
cedures, is a complex matter. Infection develops most 
often within a bone implanted with foreign material on 
which pathogens will adhere and enter a slow-growing 
phase, causing the foreign material to become coated 
with slime. This explains the very low success rate 
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of treatments involving antibiotics alone. Thorough 
surgical treatment with removal of all suspect tissue and 
foreign material is required in addition to a prolonged 
course of antimicrobial therapy [l-41. Most frequently 
involved pathogens include Staphylococcus aweus and 
Staphylococcus epidermidis. Methicillin-resistant strains 
have emerged with reduced susceptibility to quinolones, 
rifampicin and fosfomycin, which are also indicated in 
the treatment of bone infections [ 5 ] .  In these instances, 
one of the remaining possibilities is to treat with 
glycopeptides (teicoplanin and vancomycin). The use 
of teicoplanin is limited by the existence of resistant 
strains [6,7]. The usual route of administration for 
vancomycin is repeated infusion. The other recognized 
possibility is continuous intravenous infusion, which 
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complies best with the time-dependent activity of 
vancoinycin by maintaining constant serum levels, and 
provides better tissue diffusion and tolerance [8]. This 
study was undertaken to evaluate the safety and efficacy 
of prolonged treatment with continuous vancomycin in 
chronic postoperative Gram-positive bone and joint 
infection. 
PATIENTS AND METHODS 
Study population 
A patient was included in the study when the following 
criteria were met: clinical evidence of chronic bone 
and joint infection (chronic pain or draining sinuses 
from the involved areas of at least 1 month's duration); 
evidence that the initial infection appeared after an 
open fracture or elective orthopedic procedure; evi- 
dence ofbone and joint infection on radiograph studies 
and/or radionuclide imaging (technetium polyphos- 
phate, ')""'Tc and gallium scans), and/or magnetic 
resonance imaging; isolation of bacterial pathogens 
susceptible to vanconiycin from a bone biopsy specimen 
or from aspirated joint fluid-the isolated pathogens 
were tested for in vitro susceptibility to vancomycin 
using standard methods, and MICs and MBCs for 
isolated organisms were determined by the standard 
tube dilution technique in Mueller-Hinton Broth; no 
history of allergy to glycopeptides. 
Treatment protocol 
All the patients were initially given a 40 mg/kg/day 
vanconiycin infusion over 24 h without a loading dose. 
The 24 h dose was adjusted to maimain serum levels 
between 25 and 35 mg/L. An intravenous access system 
was implanted in each patient at the beginning of 
the treatment. Vancomycin was administered via an 
ambulatory delivery system to allow home antibiotic 
therapy. The system used was a Cadd 1 pump (Phar- 
macia Deltec). Additional antibiotics were given when 
the associated bacteria were resistant to vancomycin 
therapy. Whenever this was possible, surgical debride- 
nient and removal of foreign material was performed at 
the beginning of the treatment course. 
Antibiotics were administered for 6 months. They 
were continued for over 6 months if the clinician 
believed that the therapy was effective but the infection 
had not totally resolved. Initial treatment admini- 
stration was conducted on hospitalized patients who 
were monitored for 2 weeks before being discharged. 
They were subsequently treated at home with day- 
hospital follow-up. Regular replacement of the intra- 
venous line and vancomycin cassette was ensured by 
day-hospital or home-care nurses trained in the use of 
this device. 
Clinical monitoring and scheduling 
Clinical assessment was conducted daily during hoqpital- 
ization, then twice monthly until the end of treatment, 
and at the follow-up visits (3, 6 and 12 months). 
Pre-therapy tests included blood count, erythrocyte 
sedimentation rate, C reactive protein, creatinemia, 
glutamic pyruvic and glutarnic oxaloacetic transaminases, 
alkaline phosphatases and urinalysis. They were re- 
peated once a week during hospitalization, and then 
every 2 weeks and at follow-up visits. Audiometry 
tests were performed at the beginning and a t  the end 
of treatment and in case of any clinical symptom. 
Repeated imaging studies (radiographs, isotopic bone 
scans and, if possible, magnetic resonance imaging) 
were performed 3 months after the beginning of treat- 
ment, at the end of treatment, and between 3 and 6 
months and again 12 months after ending treatment. 
Vanconiycin serum level was determined daily by 
fluorescence polarization imiiiunoassay until the preset 
value was obtained, weekly during hospitalization, and 
twice a month on an outpatient basis. Whenever pos- 
sible, bone samples were collected with the patient's 
consent by iliac crest biopsy. The specimens were 
pulverized and eluted into phosphate buffer and the 
supernatants were analyzed for vanconiycin content by 
microbiological assay as well as on a simultaneous blood 
sample. 
Determination of outcome 
Success was defined as at least the following criteria 
being satisfied a t  the end of therapy and after a 
minimum follow-up period of 6 months: resolution of 
clinical symptoms; a gallium scan that appeared normal 
or showed significant improvement; and/or regression 
of focal inflammatory lesions on magnetic resonance 
imaging. 
Persistence or recurrence of clinical symptoms 
and/or isolation of the same pathogen(s) were defined 
as failure. 
Patient characteristics 
Fifteen patients with Gram-positive chronic bone 
and joint infection received vancomycin. Duration of 
chronic infection ranged from 6 weeks to 10 years. 
There were 12 men and three women with a mean age 
of 61.7 years (range 23-90 years) and a mean weight of 
70 kg (range 46-85 kg). Infection sites included hip 
and femur (10 patients), tibia (three patients), knee and 
patella (one patient) and vertebrae (one patient). The 
precipitating events were: prosthetic replacement in 
eight patients, tibia1 open fracture osteosynthesis in 
two patients, acetabular fracture osteosynthesis in two 
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patients, closed tibial fracture osteosynthesis in one 
patient, knee joint arthroplasty in one patient, and 
laiiiinectoniy for lumbar canal stenosis in one patient 
(Table I). 
Patients were treated with vancomycin for a mean 
duration of 184 days (range 120-235). Concomitant 
surgical management included sequestrectoriiy in two 
patients, removal of prosthetic hip in seven patients, 
removal of metal implant in one patient, debridenient 
without removal of the hip prosthesis in one patient and 
perivertebral abscess drainage in one patient. Among 
patients with prosthesis removal, two had a secondary 
hip replacement through a two-stage surgical procedure. 
Keiiiiplantation of a prosthesis was not possible in the 
other patients, due to the severity ot' adjacent bone 
lesions. 
Bacteriological results 
Eighteen pathogens were isolated from the 15 patients 
either from bone biopsy, collected at the time of 
surgical debridenlent, or needle aspirate. Bacteria 
involved were Stuphylococcus u w w r  (eight), among which 
six were resistant to niethicillin (MKSA), Staphylococcus 
epidevmidis (four), all resistant to niethicillin (MKSE), 
Stucpfococcur bovis (one), Eliteyococcus auiurn (one), and 
Entevo~occLls-fdeciUMz (one). In one patient, Proteus w~ivubilis, 
E. coli and Bactevoides sp. were recovered from the 
bone biopsy in addition to Enterococcids faecalis. MICs 
of vancomycin for the Gram-positive isolates ranged 
from 1 to 4 mg/L. 
Vancomycin dosage and serum and bone vancomycin levels 
After initial dose adjustment, the mean weight-related 
dosage ranged from 26mg/kg to 47mg/kg for 14 
patients. One patient with prior renal iinpairnient 
received a daily dose of 15 nig/kg. Mean concentration 
as measured by fluorescent polarization assay was 28.7 & 
4.5 mg/L with a median of 28 rng/-L. An iliac crest 
bone biopsy was performed in six patients after a treat- 
ment course of at  least 15 days. Concentration of 
vanconiycin by the microbiological method after 
multiple extractions gave a mean concentration of 
67.7k38.9 pg per gram of non-infected bone tissue. 
Because of the sinall size of the bone samples, separate 
concentration of vancomycin in cortical bone and 
cancellous bone was not performed. 
Outcome 
Based on a mean post-treatment follow-up of 14&4 
months (range 6-20.6), the infection was arrested in 10 
patients (66.6%)) (Table 1). 
One primary failure occurred during treatment. 
This patient (no. 4) had a 4-year history of sepsis of a 
tibial fracture site with a double sinus and a large 
sequestrum. Removal of the sequestruni was performed 
prior to treatment. Several organisms were involved: 
EI.lteroccocirs~eculis, E. mli, Pvotcirr inirabilis and Buctevoides 
sp. In addition to vanconiycin, this patient received 
ceftriaxone and metronidazole. The course was initially 
favorable, with partial subsidence of sinus disclixge and 
partial closure of the sinus orifices. After a treatment 
period of 4 months, there was a recurrence of sinus 
discharge with re-isolation of the initial pathogens 
and no improvement on radionuclide and magnetic 
resonance imaging. Four secondary failures occurred 
with a mean delay of 53 days (range 30-90) after 
discontinuation of therapy. The first patient (no. 3) 
presented with sepsis related to a hip prosthesis with 
involvement of adjacent bone tissue. Surgical treatment 
consisted of drainage of a periprosthetic abscess due to 
MRSA. Vanconiycin treatment resulted in sinus 
closure, while pain and inflammation subsided. Kelapse 
occurred 53 days after treatment was discontinued, with 
reopening of the sinus orifice and re-isolation of the 
sarne pathogen. The second patient (no. 6) presented 
with sepsis following pelvic, acetabular and greater 
trochanter osteosynthesis after multiple fractures. 
Thorough surgical debridenient was not possible. 
Treatment resulted in closure of the draining sinus 
and regression of the inflammatory syndrome. It  was 
considered as a failure 3 months after discontinuation 
when radiologic findings showed destruction of the hip 
joint with a dense and heterogeneous aspect of the 
acetabuluni and iliac bone and persisting hypen'ix~tion 
on the gallium scan. The third patient (no. 14) had 
chronic MRSA infection of the knee following 
iniplantation of a trochlear shield. Surgical treatment 
consisted of total synovectomy and condylotibial 
arthroplasty with no removal of foreign material. After 
6 months of treatment, the inflammatory syndrome 
had completely resolved. Persistence of hyperfixation 
within the fernorotibial joint space on the gallium 
scan led to prolongation of treatment for two inore 
months. Both needle aspirates of the knee joint per- 
formed during treatment because of a mild effusion 
were sterile. Recurrence was noted 40 days after 
stopping treatment, when major effusion of the 
knee joint developed with re-isolation of the same 
pathogen. 
The last treatment failure (no. 13) concerned a 
patient with MSSA prosthetic hip infection. Upon 
removal of the prosthesis, a large abscess was discovered 
adjacent to the greater trochanter. At the end of the 
antibiotic treatment course, the inflammatory signs had 
resolved, gallium fixation was normal and there was 
no sign of pus collection. A month later the patient 
had mild pyrexia and elevated C reactive protein. Ultra- 
sonic examinations showed a hypoechogen collection 
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around the trochanter from which the same MSSA was 
recovered with an MIC of 1 pg/mL and an MBC of 
16 pg/mL. 
Adverse effects 
Adverse events occurring in our patients were analyzed 
by the Committee on Safety of Medicine of Nice. 
Five patients experienced adverse events with a 
probable relation to vancomycin: three (nos. 12, 13 and 
14) had a moderately increased creatinine serum level 
(grade 1) which appeared after the second month of 
treatment for two patients and after the seventh month 
for the last patient, with vancomycin levels ranging 
from 40 to 43.5 mg/L; two patients had transient 
neutropenia, and in one patient (no. 6) neutropenia 
(550 neutrophils/mm3) developed after 20 days of 
treatment and was associated with a high vancomycin 
serum level (49.5 mg/L). Treatment was discontinued 
until the neutrophil count returned to normal (6 days). 
No recurrence of neutropenia was noted after reintro- 
duction of vancomycin at a lower dose. In the other 
patient (no. 8) the drop in neutrophil count (900/mm3) 
occurred after 6 weeks' treatment duration. Vancomycin 
serum level was then 35 mg/L. This patient com- 
plained at the same time of tinnitus. The audiogram 
showed a high-frequency 10-dB hearing loss in the left 
ear which could be related to vancomycin admini- 
stration. Adverse events having a possible relation with 
vancomycin included: pruritus, which appeared in 
four patients between 30 and 120 days of treatment 
and resolved spontaneously in one patient and after 
antihistamine therapy in the other three; and transient 
tinnitus in one patient at  75 days of treatment with 
no change on the audiogram. At least four patients 
developed dermatophytosis of the face, thorax, inguinal 
fold, and scalp which resolved with specific topical 
treatment. One patient presented with an infection 
of the indwelling intravenous access system at the end 
of treatment which required removal of the infected 
material. Proteus mirubilis was the involved pathogen. 
N o  treatment was permanently discontinued. In 
the three patients with mild creatinemia elevation, daily 
dosage of vancomycin was adjusted to maintain serum 
levels within the preset values. In the patient with 
neutropenia and tinnitus, dosage was reduced to 20 
mg/kg/day resulting in resolution of auditory and 
blood count disorders while maintaining a serum level 
of vancomycin of 20 mg/L. 
DISCUSSION 
This study confirms that prolonged continuous 
vancomycin infusion is effective for the treatment 
of chronic bone and joint infections caused by Gram- 
positive bacteria, including methicillin-resistant staphy- 
lococci. Our success rate after a mean follow-up of 14 
months was 66%. These results are comparable to those 
obtained with teicoplanin which offers an alternative 
for the treatment ofMRSA chronic osteitis [9,10]. Few 
data are available concerning the treatment of bone 
infection with vancomycin. Animal studies on either 
the rabbit or the rat model show diverging results. O n  
a model involving MSSA, Norden and Shaffer [ll] 
demonstrated poor efficacy of vancomycin and its 
possible relation to the low oxygen tensions found in 
osteomyelitic bone. O n  the other hand, on a model 
involving MRSA, vancomycin resulted in sterilization 
ofinfected bone in 40% ofthe animals [12]. In the small 
series of patients reported in the literature [13,14], 
vancomycin is used in repeated infusion of variable 
dosage and treatment duration. In Fitzpatrick's series 
[14], six out of 10 patients experienced no recurrence 
during a 2-year follow-up period. Nevertheless, 
repeated administration of the antibiotic, requiring 
hospitalization, is a limiting factor. Several arguments 
lead to the use of continuous vancomycin infusion. 
First, it ensures better tissue diffusion. Data are scarce 
concerning diffusion within bone tissue. However, 
results of a study conducted by Desplaces et a1 [15] on 
a limited number of non-infected samples show that 
concentrations obtained after continuous infusion are 
markedly higher (65.6+36 pg per gram of bone tissue 
(median, 56; range lb/cortical bone to 130/cancellous 
bone)), than those obtained with discontinuous infusion 
[16-181. We have obtained similar results with iliac 
crest biopsy samples. Second, several clinical studies 
have demonstrated the efficacy of continuous vanco- 
mycin infusion in various MRSA infections [19]. In the 
published series, administered doses ranged from 30 to 
50 mg/kg/day with or without aloadingdose [8,15,19]. 
In fact, dosage must be correlated with the required 
concentration at the site of infection. This should 
theoretically be 8-10 times the MIC for the involved 
pathogens [20]. Third, tolerance is improved; no 
incidence of red man syndrome has been reported in 
any of the studies. In our series, the clinical and 
biological tolerance of vancomycin continuous infusion 
over 6 months was satisfactory. No treatment course 
was permanently discontinued because of major in- 
tolerance. Adverse effects with a probable relation to 
vancomycin included leucopenia, mild elevation of 
creatinemia and tinnitus. These disturbances were 
associated with vancomycin serum levels >35 mg/L 
during regular follow-up. Dose readjustment resulted 
in all cases in partial or complete regression of the 
observed abnormalities. Biological disturbances dis- 
appeared upon discontinuation of treatment in each 
case. The patient (no. 8) whose a d o g r a m  had revealed 
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mild ototoxicity remained stable and even improved 
at the last check-up visit. Nevertheless, long-term 
administration of vancoinycin requires a reliable intra- 
venous line and the fitting of a continuous infusion 
system. The Cadd 1 pump is a peristaltic pump that 
delivers the drug from a cassette vvhich generally 
contains a 72 h dose of vancomycin, thus restricting the 
number of manipulations. Finally, the use of a small 
portable computer-controlled pump allows the patient 
not only to leave the hospital but also to assume many 
normal activities of daily life. 
Our study, like those ofFitzpatrick et a1 [14], shows 
that success depends on the initial surgical treatment 
(debridenlent and/or removal of foreign material) 
associated with medical treatment. Outcome was 
successful in seven of the eight patients in whom 
removal of the foreign material was performed initially, 
and in three patients with either initial sequestrectomy 
or abscess drainage. Treatment failures were related to 
inadequate debridenlent and persistence of foreign 
material (three patients) and irradiated bone (one 
patient). In the presence of foreign material, various 
factors may account for treatment failure: non-pene- 
tration of the antibiotic within the biofilm, changes in 
the immune response in the presence of foreign 
material, slow-growing pathogens. Darouiche’s study 
of an in vitro model for prosthesis-related infection 
shows that the failure of vanconiycin to cure prosthesis 
infection is not due to its poor penetration in the 
bioflm, but is related to a low antimicrobial effect on 
bacteria within the biofilni environment [21]. 
The duration of antibiotic treatment in chronic 
bone and joint infection has not been entirely deter- 
mined. Recommendations vary, ranging from a few 
weeks to several years [2]. Moreover, there is no 
consensus on the necessity of continuing antibiotic 
therapy after removal of foreign material or extensive 
curettage, or on its duration. Nevertheless, difficulties 
in removing all infected bone during surgical debride- 
nient, resulting in a high recurrence risk due to 
microscopic infection, underline the necessity of a 
prolonged treatment [22]. Furthermore, in case of 
infected prosthesis, a short treatment course associated 
with a one- or two-stage replacement procedure resulted 
in a success rate of only 35%, while it reached 90% with 
long-term antibiotic treatment [23,24]. 
In conclusion, although our study concerns a 
limited number of patients, prolonged treatment with 
vanconiycin continuous intravenous infusion appears to 
be safe and effective for the treatment of Cram-positive 
chronic bone infection, providing thorough surgical 
treatment is initially performed, including removal 
of d l  foreign material. It ensures higher bone tissue 
concentrations than those obtained with intermittent 
infusion and allows outpatient treatment via an ainbu- 
latory delivery system, thus improving the patient’s 
comfort and reducing the overall cost of treatment. 
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